EGFR and non-small cell lung carcinoma: Gefitinib (A), shown in Figure 1, is an example of a trisubstituted 4-anilinoquinazoline drug used for the treatment of non-small-cell lung cancer (NSCLC) with sensitive mutations of the EGFR [4].